OKYO Pharma Limited carries no debt; cash flow comfortably covers obligations.

OKYO Pharma Limited's free cash flow has increased -80.91% from $-9.49M last year to $-1.81M, signaling increasing performance

OKYO Pharma Limited's debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

OKYO Pharma Limited has insufficient data to evaluate this check.

OKYO Pharma Limited has a net cash position, so leverage is healthy.

OKYO Pharma Limited carries no debt; interest obligations are fully covered.

OKYO Pharma Limited has insufficient data to evaluate this check.

OKYO Pharma Limited's short-term assets of $20.97M exceed its short-term liabilities of $8.64M

OKYO Pharma Limited's return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

OKYO Pharma Limited's return on equity of -200.67%, is lower than 15.00%, indicating bad performance

OKYO Pharma Limited's operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

OKYO Pharma Limited has insufficient public price history to evaluate earnings stability.

OKYO Pharma Limited has negative free cash flow, indicating the company is burning cash rather than generating it

OKYO Pharma Limited has negative free cash flow, indicating cash burn

OKYO Pharma Limited's yearly earnings has decreased 90.16% since last year from $-4.71M to $-8.95M, signaling decreasing performance

OKYO Pharma Limited's yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -74.59% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

OKYO Pharma Limited has insufficient revenue history to calculate 3-year revenue CAGR.

OKYO Pharma Limited had revenue growth in 5 out of 5 years, indicating consistent revenue performance

OKYO Pharma Limited has insufficient public price history to evaluate ROE consistency.

OKYO Pharma Limited has insufficient data to evaluate this check.

OKYO Pharma Limited has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

OKYO Pharma Limited is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

OKYO Pharma Limited has negative or missing EBITDA, making EV/EBITDA ratio unreliable

OKYO Pharma Limited has insufficient data to evaluate this check.

OKYO Pharma Limited has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

OKYO Pharma Limited has a price-to-book ratio of 4.76x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

OKYO Pharma Limited has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue